Malignancy-Associated Hypercalcemia and Medical Management

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 1, Issue , 2010, Pages 1198-1211

  Horwitz, Mara J ^a   Stewart, Andrew F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018607082     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00063-0     Document Type: Chapter

References (130)

1. H Zondek, H Petow and W Siebert (1923) Die bedeutung der calciumbestimmung im blute fur die diagnose der niereninsuffzientz. Z Klin Med 99 129-138.
2. AB Gutman, TL Tyson and EB Gutman (1936) Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic disease of the bones. Arch Intern Med 57 379-413.
3. Case records of the Massachusetts General Hospital (case 27461). N Engl J Med 225 789-791.
4. CH Plimpton and A Gelhorn (1956) Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med 21 750-759.
5. TB Connors and JF Howard (1956) The etiology of hypercalcemia associated with lung carcinoma. J Clin Invest 35 697-698.
6. FW Lafferty (1966) Pseudohyperparathyroidism. Medicine (Baltimore) 45 247-260.
7. JS Rodman and LM Sherwood (1978) Disorders of mineral metabolism in malignancy. LV Avioli, SM Krane,(Eds) Metabolic Bone Disease vol 2 New York: Academic Press 555-631.
8. WPL Myers (1960) Hypercalcemia in neoplastic disease. Arch Surg 80 308.
9. A Besarab and JF Caro (1978) Mechanisms of hypercalcemia in malignancy. Cancer 41 2276-2285.
10. D Powell, FR Singer, TM Murray, et al. (1973) Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. N Engl J Med 289 176-181.
11. AF Stewart, R Horst, LJ Deftos, et al. (1980) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med 303 1377-1383.
12. JW Godsall, WJ Burtis, KL Insogna, et al. (1986) Nephrogenous cyclic AMP, adenylate cyclase–stimulating activity, and the humoral hypercalcemia of malignancy. Recent Prog Horm Res 40 705-750.
13. AF Stewart, A Vignery, A Silvergate, et al. (1982) Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Metab 55 219-227.
14. SH Ralson, SJ Gallagher, U Patel, et al. (1990) Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med 112 499-504.
15. DW Nierenberg and BJ Ransil (1979) Q-aTc interval as a clinical indicator of hypercalcemia. Am J Cardiol 44 243-248.
16. TME Davis, B Singh, KE Choo, et al. (1995) Dynamic assessment of the electrocardiographic QT intervals during citrate infusion in healthy volunteers. Br Heart J 75 523-526.
17. GS Omenn, SI Roth and WH Baker (1969) Hyperparathyroidism associated with malignant tumors of non-parathyroid origin. Cancer 24 1004-1012.
18. P Skrabanek, J McPartlin and DM Powell (1980) Tumor hypercalcemia and ectopic hyperparathyroidism. Medicine (Baltimore) 59 262-282.
19. WJ Burtis, TG Brady, JJ Orloff, et al. (1990) Immunochemical characterization of circulating parathyroid hormone–related protein in patients with humoral hypercalcemia of malignancy. N Engl J Med 322 1106-1112.
20. AR Budayr, RA Nissenson, RF Klein, et al. (1989) Increased serum levels of PTH-like protein in malignancy-associated hypercalcemia. Ann Intern Med 111 807-810.
21. E Blind, F Raue, J Gotzman, et al. (1992) Circulating levels of mid-regional parathyroid hormone-related protein in hypercalcemia of malignancy. Clin Endocrinol 37 290-297.
22. MR Pandian, CH Morgan, E Carlton, et al. (1992) Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin Chem 38 282-288.
23. RA Bender and H Hansen (1974) Hypercalcemia in bronchogenic carcinoma: a prospective study of 200 patients. Ann Intern Med 80 205-208.
24. PS Mahadevia, A Pamaswamy, ES Greenwald, et al. (1983) Hypercalcemia in prostatic carcinoma. Arch Intern Med 143 1339-1342.
25. S Ralston, I Fogelman, MD Gardner, et al. (1982) Hypercalcemia and metastatic bone disease: is there a link? Lancet 2 903-905.
26. GR Mundy, LG Raisz, RA Cooper, et al. (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 290 1041-1046.
27. GR Mundy, RA Luben, LG Raisz, et al. (1974) Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med 290 867-871.
28. NS Callander and GD Roodman (2001) Myeloma bone disease. Semin Hematol 38 276-285.
29. MJ Horwitz and AF Stewart (2006) Malignancy-Associated Hypercalcemia. M Favus,(Eds) The American Society for Bone and Mineral Research Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism ed 6 Washington D.C.: American Society for Bone and Mineral Research 195-199.
30. FE Dewhirst, PP Stashenko, JE Mole, et al. (1985) Purification and partial sequence of human osteoclast activating factor: identity with human interleukin lB. J Immunol 135 2562.
31. GD Roodman (2004) Mechanisms of bone metastasis. N Engl J Med 350 1655-1664.
32. FP Ross (2006) Osteoclast Biology and Bone Resorption. M Favus,(Eds) The American Society for Bone and Mineral Research Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism ed 6 Washington D.C.: American Society for Bone and Mineral Research 30-35.
33. E Tian, F Zhan, R Walker, et al. (2003) The role of the Wnt/beta-catenin signaling antagonist DKK-1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 2483-2494.
34. LA Erlich, HY Chung, I Ghobrial, et al. (2005) IL-3 is apotent inhibitor of osteoblast differentiation in multiple myeloma. Blood 106 1407-1414.
35. CSB Galasko (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263 507.
36. TA Guise, JJ Yin, SD Taylor, et al. (1996) Evidence for a causal role of parathyroid hormone–related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98 1544.
37. J Southby, MW Kissin, JA Danks, et al. (1990) Immunohistochemical localization of PTHrP in human breast cancer. Cancer Res 50 7710-7716.
38. SJ Vargas, MT Gillespie, GJ Powell, et al. (1992) Localization of PTHrP mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 7 971-979.
39. M Sztern, A Barkan, E Rakowsky, et al. (1981) Hypercalcemia in carcinoma of the breast without evidence of bone destruction. Cancer 48 2383-2385.
40. SS Legha, K Powell, AU Buzdar, et al. (1981) Tamoxifen-induced hypercalcemia in breast cancer. Cancer 47 2803-2806.
41. A Valentin-Opran, G Eilon, S Saez, et al. (1985) Estrogens stimulate release of bone-resorbing activity in cultured human breast cancer cells. J Clin Invest 72 726-731.
42. K Nakayama, S Fukumoto, S Takeda, et al. (1996) Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81 607-611.
43. V Grill, P Ho, JJ Body, et al. (1991) PTH-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol 73 1309-1315.
44. C Isales, ML Carcangiu and AF Stewart (1987) Hypercalcemia in breast cancer: a reassessment of the mechanism. Am J Med 82 1143-1147.
45. S Fukumoto, T Matsumoto, T Ikeda, et al. (1988) Clinical evaluation of adult T-cell lymphoma. Arch Intern Med 148 921-925.
46. T Wantabe, K Yamaguchi, K Tatasuki, et al. (1990) Constitutive expression of PTHrP gene in HTLV-1 carriers and adult T-cell leukemia patients that can be trans-activated by HTLV-1 tax gene. J Exp Med 172 759-765.
47. T Mune, H Katakami, Y Kato, et al. (1993) Production and secretion of parathyroid hormone-related protein in pheochromocytoma: participation of an α-adrenergic mechanism. J Clin Endocrinol Metab 76 757-762.
48. AF Stewart, J Hoecker, GV Segre, et al. (1985) Hypercalcemia in pheochromocytoma: evidence for a novel mechanism. Ann Intern Med 102 776-779.
49. C Mao, P Carter, P Schaefer, et al. (1997) Malignant islet cell tumor associated with hypercalcemia. Surgery 117 37-40.
50. T-J Wu, C-L Lin, RL Taylor, et al. (1997) Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 72 1111-1115.
51. S Dagdelen, I Kalan and A Gurlek (2008) Humoral hypercalcemia of benignancy secondary to parathyroid hormone-related protein secreting uterine leiomyoma. Am J Med Sci 335 407-408.
52. GS Gordan, ME Fitzpatrick and WP Lubich (1967) Identification of osteolytic sterols in human breast cancer. Trans Assoc Am Physicians 80 183-189.
53. JG Haddad, SJ Couranz and LV Avioli (1970) Circulating phytosterols in normal females, lactating mothers, and breast cancer patients. J Clin Endocrinol Metab 30 174-180.
54. DC Klein and LG Raisz (1970) Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 86 1436-1440.
55. AH Tashjian (1978) Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Res 38 4138-4141.
56. WJ Seyberth, GV Segre, JL Morgan, et al. (1975) Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 293 1278-1283.
57. D Brenner, HA Harvey, A Lipton, et al. (1982) A study of prostaglandin E2 parathormone, and response to indomethacin in patients with hypercalcemia and malignancy. Cancer 49 556-561.
58. RC Benson, BL Riggs, BM Pickard, et al. (1974) Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. Am J Med 56 821-826.
59. BL Riggs, CD Arnaud, JC Reynolds, et al. (1971) Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J Clin Invest 50 2079-2083.
60. M Everhart-Caye, SE Inzucchi, J Guinness-Henry, et al. (1996) Parathyroid hormone-related protein(1–36) is equipotent with parathyroid hormone(1–34) in humans. J Clin Endocrinol Metab 81 199.
61. JG Henry, MA Mitnick, PR Dann, et al. (1997) Parathyroid hormone-related protein(1–36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82 900-906.
62. MA Syed, MJ Horwitz, MB Tedesco, et al. (2001) Parathyroid hormone-related protein (1–36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 86 1525-1531.
63. MJ Horwitz, MB Tedesco, S Sereika, et al. (2003) Direct comparison of sustained infusion of hPTHrP(1-36) versus hPTH(1-34) on serum calcium, plasma 1,25(OH)2 vitamin D concentrations and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88 1603-1609.
64. MJ Horwitz, MB Tedesco, SM Sereika, et al. (2005) Continuous infusion of parathyroid hormone versus parathyroid hormone-related protein in humans: discordant effects on 1,25(OH)2 vitamin D and prolonged suppression of bone formation. J Bone Miner Res 20 1792-1803.
65. A Stewart, M Mangin, T Wu, et al. (1988) A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 81 596-600.
66. J Henderson, S Bernier, P D’Amour, et al. (1990) Effects of passive immunization against PTH-like peptide in hypercalcemic tumor-bearing rats and normocalcemic controls. Endocrinology 127 1310-1316.
67. SC Kukreja, DH Shevrin, SA Wimbiscus, et al. (1988) Antibodies to PTH-related protein lower serum calcium in athymic mouse models of malignancy associated hypercalcemia due to human tumors. J Clin Invest 82 1798-1802.
68. WM Philbrick, JJ Wysolmerski, S Galbraith, et al. (1996) Defining the physiologic roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76 127-173.
69. GJ Strewler (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342 177-185.
70. SR Nussbaum, RJ Zahradnik, JR Lavigne, et al. (1987) Highly sensitive two-site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33 1364-1367.
71. T Dean, J-P Vilardaga, JT Potts, et al. (2008) Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22 156-166.
72. RC Coombes, MK Ward, PB Greenberg, et al. (1976) Calcium metabolism in cancer. Studies using calcium isotopes and immunoassay for parathyroid hormone and calcitonin. Cancer 38 2111-2120.
73. SH Ralston, I Fogelman, MD Gardner, et al. (1984) Hypercalcemia of malignancy: evidence for a non-parathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci 66 187-194.
74. J-P Bonjour, J Phillipe, G Guelpa, et al. (1988) Bone and renal components in hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 9 123-130.
75. SR Nussbaum, RD Gaz and A Arnold (1990) Hypercalcemia and ectopic secretion of PTH by an ovarian carcinoma with rearrangement of the gene for PTH. N Engl J Med 323 1324-1328.
76. K Yoshimoto, R Yamasaki, H Sakai, et al. (1989) Ectopic production of PTH by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68 976-981.
77. GJ Strewler, AA Budayr, OH Clark, et al. (1993) Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 76 1373-1375.
78. H Iguchi, C Miyagi, K Tomita, et al. (1998) Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. J Clin Endocrinol Metab 83 2653-2657.
79. PK Nielsen, AK Rasmussen, U Feldt-Rasmussen, et al. (1996) Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 81 3793-3796.
80. R Rizzoli, J-C Pache, L Didierjean, et al. (1994) A thymoma as a cause of true ectopic hyperparathyroidism. J Clin Endocrinol Metab 79 912-915.
81. HJ Schmeltzer, RD Hesch and H Mayer (1985) Parathyroid hormone and PTH mRNA in a human small cell lung cancer. Recent Results Cancer Res 99 88-93.
82. JN VanHouten, NY Yu, D Rimm, et al. (2006) Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 91 580-583.
83. SA Metz, JR McRae and RP Robertson (1981) Prostaglandins as mediators of paraneoplastic syndromes: review and update. Metabolism 30 299-316.
84. N Rosenthal, KL Insogna, JW Godsall, et al. (1985) Elevations in circulating 1,25 dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab 60 29-33.
85. NA Breslau, JL McGuire, JE Zerwekh, et al. (1984) Hypercalcemia associated with increased serum 1,25 dihydroxyvitamin D in three patients with lymphoma. Ann Intern Med 100 1.
86. JF Seymour, RF Gagel, FB Hagemeister, et al. (1994) Calcitriol production in hypercalcemia and normocalcemia patients with non-Hodgkin lymphoma. Ann Intern Med 121 633-640.
87. KN Evans, H Taylor, D Zehnder, et al. (2004) Increased expression of 25-hydroxyvitamin D-1-alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 165 807-813.
88. H Masahito, F Hara, H Tomishige, et al. (2008) 1,25-Dihydroxyvitamin D–mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 25 73-78.
89. AF Stewart, AE Broadus, PE Schwartz, et al. (1982) Hypercalcemia in gynecologic neoplasms. Cancer 49 2389-2394.
90. FR Bringhurst, BE Bierer, F Godeau, et al. (1986) Humoral hypercalcemia of malignancy. J Clin Invest 77 456-464.
91. FR Bringhurst, V Varner and GV Segre (1982) Cancer-associated hypercalcemia: characterization of a new bone-resorbing factor [Abstract]. Clin Res 30 386.
92. JP Bilezikian (1992) Management of acute hypercalcemia. N Engl J Med 326 1196-1203.
93. AF Stewart (2005) Hypercalcemia associated with cancer. N Engl J Med 352 373-379.
94. MJ Horwitz, S Hodak and AF Stewart (2008) Non-Parathyroid Hypercalcemia. CJ Rosen,(Eds) The American Society for Bone and Mineral Research Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism ed 7 Washington D.C.: American Society for Bone and Mineral Research
95. WN Suki, JJ Yium, M Von Minden, et al. (1970) Acute treatment of hypercalcemia with furosemide. N Engl J Med 283 836-840.
96. DJ Hosking, A Cowley and CA Bucknall (1981) Rehydration in the treatment of severe hypercalcaemia. Q J Med 50 473-481.
97. H Fleisch (1998) Bisphosphonates: mechanism of action. Endocr Rev 19 80-100.
98. RG Russell and MJ Rogers (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 97-106.
99. D Black and CJ Rosen (2006) Bisphosphonates for the Prevention and Treatment of Osteoporosis. M Favus,(Eds) The American Society for Bone and Mineral Research Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism ed 6 Washington D.C.: American Society for Bone and Mineral Research 30-35.
100. GA Rodan and HA Fleisch (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97 2692-2696.
101. SM Cheer and S Noble (2001) Zolendronic acid. Drugs 61 799-805.
102. JC Frith and MJ Rogers (2003) Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18 204-212.
103. P Major, A Lortholary, J Hon, et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized controlled clinical trials. J Clin Oncol 19 558-567.
104. JJ Body, A Lortholary, G Romieu, et al. (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14 1557-1561.
105. S Nussbaum, J Younger, C VandePol, et al. (1993) Single dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95 297-304.
106. S Adami, AK Bhalla, R Dorizzi, et al. (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41 326-331.
107. GS Markowitz, GB Appel, PL Fine, et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 1164-1172.
108. LS Rosen, D Gordon, M Kaminski, et al. (2003) Long-term efficacy and safety of zoledonic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8), 1735-1744.
109. CP Perlia, NJ Gubisch, J Wolter, et al. (1970) Mithramycin treatment of hypercalcemia. Cancer 25 389-394.
110. BJ Kennedy (1970) Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49 494-503.
111. DJ Hosking and D Gilson (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 53 359-368.
112. M Cochran, M Peacock, G Sachs, et al. (1970) Renal effects of calcitonin. BMJ 1 135-137.
113. OL Silva and KL Becker (1973) Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 132 337-339.
114. S Kammerman and RE Canfield (1970) Effect of porcine calcitonin on hypercalcemia in man. J Clin Endocrinol Metab 31 70-75.
115. LA Wisneski, WP Croom, OL Silva, et al. (1978) Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 24 219-222.
116. RP Warrell Jr, R Israel, M Frisone, et al. (1988) Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 108 669-674.
117. DH Fulmer, AB Dimich, EO Rothschild, et al. (1972) Treatment of hypercalcemia, comparison of intravenously administered phosphate, sulfate, and hydrocortisone. Arch Intern Med 129 923-930.
118. RC Percival, AJ Yates, RE Gray, et al. (1984) Role of glucocorticoids in management of malignant hypercalcaemia. BMJ 289 287.
119. C Camus, C Charasse, I Jouannic-Montier, et al. (1996) Calcium free hemodialysis: Experience in the treatment of 33 patients with severe hypercalcemia. Intensive Care Med 22 116-121.
120. WS Koo, DS Jeon, SJ Ahn, et al. (1996) Calcium-free hemodialysis for the management of hypercalcemia. Nephron 72 424-428.
121. CJ Cardella, BL Birkin and A Rapoport (1979) Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol 12 285-290.
122. KD Nolph, M Stoltz and JF Maher (1971) Calcium free peritoneal dialysis, treatment of vitamin D intoxication. Arch Intern Med 128 809-814.
123. JW Hamilton, M Lasrich and P Hirszel (1980) Peritoneal dialysis in the treatment of severe hypercalcemia. J Dial 4 129-138.
124. PJ Miach, JK Dawborn, TJ Martin, et al. (1975) Management of the hypercalcaemia of malignancy by peritoneal dialysis. Med J Aust 1 782-784.
125. RS Goldsmith and SH Ingbar (1966) Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 274 1-7.
126. K Sato, E Onuma, RC Yocum, et al. (2003) Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 30 167-173.
127. J-J Body, P Greipp, RE Coleman, et al. (2003) A phase I study of AMGN-00007, a recombinant osteoprotegerin construct, in patients with multiple myeloma of breast cancer related bone metastases. Cancer 97 887-892.
128. MR McClung, EM Leweicki, SB Cohen, et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 821-831.
129. HG Bone, MA Bolognese, CK Yuen, et al. (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93 2149-2157.
130. S Moroney, K Warmington, S Adamu, et al. (2005) The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146 3235.